MENA Vaccine Market

MENA Vaccine Market Size and Share:

The MENA vaccine market size was valued at USD 2.25 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 3.83 Billion by 2033, exhibiting a CAGR of 5.70% from 2025-2033. The market is driven by rising healthcare awareness, government initiatives for immunization programs, a growing population, an increasing prevalence of infectious diseases, and advancements in vaccine technologies. In addition to this, the pandemic of COVID-19 has shed light on robust vaccine distribution, which is increasing the MENA vaccine market share.

The main reason for the expanding MENA vaccine market is a growing health consciousness and the steps taken by governments to increase immunization rates. Majority of the region's countries is conducting intensive inoculation programs to prevent infectious diseases like measles, polio, and hepatitis. For example, The National Supplementary Measles Immunization Campaign 2024 was launched by the MoHAP in October 2024 to administer an additional dose of MMR vaccine to children of age within the target group. The "Protect Yourself, Protect Your Community" campaign is focused on increasing vaccination rates and achieving immunity to the virus as a part of the national measles elimination program while adhering to the universal goal of complete eradication of the disease by 2030. Governments are investing intensely in healthcare infrastructure and opening access to vaccinations in urban and rural locations. The public is now widely exposed to diseases that are controlled through vaccination, and the demand for vaccinations is stronger with the emergence of the COVID-19 epidemic, which is acting as a key growth-inducing factor. Growth in the region's immunization work also comes from global alliances and organizations, thereby further fueling the MENA vaccine market growth.

The main driver of the market is population growth and a rise in the incidences of infectious disease over recent years. The rapidly growing population in the region, along with urbanization and increased mobility, has heightened the risk of disease transmission, further underlining the need for effective vaccination programs. In addition, the emergence of new and re-emerging infectious diseases has made governments and healthcare organizations focus on vaccination. For instance, in January 2024, Saudi Arabia's Crown Prince Mohammed bin Salman announced a new initiative to strengthen the country's healthcare and localize vaccine production. National Biotechnology Strategy of Saudi Arabia also focuses on environmental protection and improved water security. The vaccines themselves have emerged as a technology with better storage means and faster production, hence vaccines are now more accessible than ever, therefore resulting in continued market growth throughout the MENA region.

MENA Vaccine Market Trends:

Government Programmes and Immunization Drive

Country-specific immunization programs and governmental initiative programs are two factors that dominantly influence the market, representing some of the key MENA vaccine market trends. The spread of infectious diseases such as polio, measles, and hepatitis is significantly reducing in various countries owing to the wide-scale immunization programs being sponsored by the respective nations. For instance, this September 2024, an emergency vaccination campaign was launched by The United Arab Emirates in the Gaza Strip on the order of President His Highness Sheikh Mohamed bin Zayed Al Nahyan to protect the over 640,000 children from polio. The program was undertaken in cooperation with the World Health Organization, UNICEF, and UNRWA and spread gradually in Gaza's northern and southern regions. This is part of an aim to ensure the prevention of the spread of polio among 90% of the children. Such programs, initiated by international organizations, promise better coverage of immunizations and vaccine access, along with a better outcome regarding public health and an enhanced MENA vaccine market demand.

Rising Healthcare Awareness

The rising awareness levels regarding health in the region have contributed significantly to the growth of the vaccine market. As the overall benefits of immunizations become clear, more people are being vaccinated to avoid infectious diseases. Increased media coverage, education initiatives, and the COVID-19 pandemic have created heightened awareness, and organizations and governments promote vaccination as part of the processes related to illness prevention and maintaining health. For instance, in April 2024, the Ministry of Public Health (MOPH) collaborated with Hamad Medical Corporation (HMC), Primary Health Care Corporation (PHCC), Sidra Medicine, and the private health sector to conduct an awareness campaign to celebrate World Immunization Week from April 24 to 30 under the theme "Humanly Possible: Saving lives through immunization."

Growing Burden of Infectious Diseases

An increasingly growing incidence of infectious diseases is another major driver for the MENA vaccine market growth. Since new diseases are emerging and old ones continue to be there, such as hepatitis and tuberculosis, vaccination turns out to be inevitable to check epidemics. Since governments tend to focus more on immunization programs to maintain public health, campaigns against polio, influenza, and COVID-19 create the fact that vaccines are still needed and thereby drive the market. For instance, in September 2024, the annual seasonal influenza vaccination campaign was launched by the Ministry of Public Health (MoPH) in collaboration with Hamad Medical Corporation (HMC) and Primary Health Care Corporation (PHCC). More than 80 medical facilities and clinics, including 31 PHCC Health Centers, in addition to outpatient clinics at HMC and various semi-government and private hospitals and clinics across Qatar, will administer free flu vaccinations for the 2024-2025 winter season starting from October 1.

MENA Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the MENA vaccine market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on product type, treatment type, technology, route of administration, patient type, indication, distribution channel, end user and country.

Analysis by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine
   

Multivalent vaccines can protect against multiple strains or types of pathogens with a single dose. This is especially helpful in areas like the Middle East and North Africa (MENA), where, for instance, hepatitis and flu are of common infectious diseases that prevail. Multivalent vaccinations are very beneficial to public health campaigns that will prevent numerous illnesses at once because they simplify immunization efforts, save costs, and increase vaccination coverage.

Monovalent vaccines are used vastly for diseases with a single causative pathogen, such as polio or hepatitis B. These vaccines show excellent efficiency in the disease caused by offering point immunity. Due to the easy usage and high efficacy of mono valent vaccines, they form a major backbone in the national immunization programs within the MENA region where there have been continuing efforts towards disease eradication. They are easier to produce, distribute, and store, thereby requiring a higher regular vaccination program.

Analysis by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine
   

The vaccination of more of the population and reducing the spread of infectious diseases are among the thrust areas in the region, thus the continued increase in demand for preventive vaccines. In regions with increased awareness and government initiatives towards health care, people want vaccination for diseases such as polio, measles, hepatitis among others to halt outbreaks and ensure protection of populations. Preventive vaccines are essential for the long-term public health initiatives in MENA nations and they are what drive demand in these nations.

Therapeutic vaccines are available for the treatment of existing infections, including cancer and chronic diseases. The region's growing healthcare infrastructure and the increasing prevalence of diseases such as cancer fuel the need for vaccines that can treat illness rather than prevent it. Therapeutic vaccinations are considered a promising invention that will help healthcare providers increase their market share in MENA as they focus on improving patient outcomes.

Analysis by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
   

Conjugate vaccinations are pretty effective at protecting against bacterial infections, especially in children. These vaccines are critical in the prevention of diseases such as meningitis and pneumococcal infections that are rampant in the region. This is achieved through the incorporation of antigens from several pathogens. They form the core of immunization initiatives in the MENA countries, thereby making them in higher demand and usage as they have the ability to enhance the immune responses among the youths.

Inactivated and subunit vaccines are easy to prepare with a safety profile. These vaccines are an important part of immunization cycles against flu and hepatitis B since they are produced using dead microorganisms or parts of them. They are an ideal candidate for national vaccination programs in MENA, assuring their continued growth due to their wide acceptability, especially in immunocompromised populations, and their good storage stability.

Live attenuated vaccines induce strong and persistent immunity. Relative to other vaccination types, these vaccines—such as the MMR vaccine—are very effective and fewer doses are needed. The steady demand and growth of their market is due to the long history of success for these vaccines in international immunization programs and also due to attempts of the region to eradicate illnesses through widespread immunization campaigns.

Analysis by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others
   

Intramuscular and subcutaneous administration methods are extensively used in delivering vaccines like COVID-19, influenza, and hepatitis. Strong immunological responses are produced by these techniques, which guarantee effective and reliable vaccination absorption. Healthcare providers in the region favor these techniques for their reliability and ease of administration in both children and adults. Their compatibility with a wide range of vaccines further intensifies their dominance in the market.

Oral vaccine administration is majorly employed due to its convenience, especially for mass immunization campaigns. Children and rural populations with limited access to healthcare might benefit greatly from oral vaccines, such as those for polio and rotavirus because they are simple to give. Particularly in extensive immunization programs, its non-invasiveness boosts acceptance rates and streamlines logistics. The efficacy of this approach in preventing infectious diseases guarantees its sustained popularity in the area.

Analysis by Patient Type:

• Pediatric
• Adult
   

Pediatric vaccines are highly in demand owing to the prioritization of childhood immunization programs. To protect young people and lower death rates, vaccines against illnesses like polio, hepatitis, and measles are crucial. The expansion of access to pediatric immunizations is a major focus of government initiatives backed by international organizations like WHO and UNICEF. The need for these vaccines is further fueled by the region's rising birth rates and parents' growing knowledge of healthcare issues.

Adult vaccines are gaining popularity as governments and healthcare providers prioritize immunization across all age groups. Immunizations against influenza, hepatitis, and COVID-19, as well as those connected to travel and the workplace, are essential for reducing adult disease outbreaks. The need for adult vaccination programs is further increased by an aging population in some MENA nations and a growing understanding of the value of vaccines and booster doses in managing chronic diseases.

Analysis by Indication:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others
     

The need for bacterial disease vaccines is being driven by the rising incidence of illnesses like meningitis, pneumonia, and diphtheria. These illnesses represent a significant health burden, especially for children and marginalized groups. Pneumococcal and meningococcal vaccinations are among the vaccines used in government-led immunization campaigns and international partnerships to prevent bacterial illnesses. The region's ongoing need for these vaccines is fueled by their vital role in preventing serious infections and lowering medical expenses.

The need for viral disease vaccines is driven by the high prevalence of diseases like COVID-19, hepatitis, and influenza. Governments prioritize immunization efforts because viral infections frequently cause serious public health issues. To prevent and treat disease, vaccines that target viral diseases, such as rotavirus and HPV, are essential. The region's need for vaccines against viral illnesses is further supported by growing knowledge, improvements in vaccine technology, and rising investments in healthcare facilities.

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others
   

Hospital pharmacies serve as primary distribution points for vaccines, particularly for critical immunizations like COVID-19 and influenza.  Hospitals frequently use their infrastructure and skilled medical personnel to provide vaccines for both routine immunizations and emergency reactions. Hospital pharmacies play a crucial role in vaccine distribution throughout the region because of their involvement in government immunization programs, patient accessibility, and capacity to handle cold storage for sensitive vaccines.

Retail pharmacies are common and convenient for people who need to be vaccinated. These pharmacies provide fast access to vaccines without requiring hospital visits, and they are crucial for routine immunizations like travel and flu shots. Their increasing significance in the local vaccine industry is a result of developing partnerships between retail pharmacies and healthcare professionals as well as increased public knowledge of the accessibility of vaccinations.

Institutional sales oversee extensive immunization programs designed to eradicate infectious illnesses and contain outbreaks, including mass purchases by governments and international organizations. They guarantee broad access in urban and rural areas thanks to their capacity to buy and distribute vaccines in large quantities. Institutional sales are further strengthened by partnerships with international health organizations like UNICEF and WHO, which makes them an essential route for the delivery of vaccines in the MENA region.

Analysis by End User:

• Hospitals
• Clinics
• Vaccination Centers
• Academic and Research Institutes
• Others
   

Hospitals are expected to hold a significant share in the MENA vaccine market as they serve as primary hubs for vaccine administration, especially for critical immunizations like COVID-19 and hepatitis. Equipped with advanced facilities, trained personnel, and cold chain systems, hospitals handle complex vaccination programs effectively. They also function as reliable healthcare professionals and are essential to national immunization programs, guaranteeing the safe and effective provision of vaccines for both routine and emergency immunizations throughout the region.

Clinics have an accessibility and major role in community healthcare. They serve patients seeking prompt and easy services by providing basic vaccinations like kid immunizations and flu shots. Additionally, clinics act as a link between major hospitals and isolated locations, increasing underprivileged communities' access to immunizations. Their contribution to the vaccine business is further strengthened by their participation in government vaccination initiatives.

Vaccination centers are critical players in the MENA vaccine market as they focus solely on immunization services, especially during large-scale campaigns like COVID-19 vaccination drives. These centers are strategically located for mass outreach, ensuring efficient delivery to urban and rural populations. Equipped with dedicated infrastructure and staff, they handle high-volume vaccine administration, making them a cornerstone for disease prevention efforts in the region.

Academic and research institutes hold a vital share in the MENA vaccine market by driving innovation and advancing vaccine development. These institutions collaborate with global organizations to conduct clinical trials, improve vaccine efficacy, and develop region-specific solutions for diseases. Their role in educating healthcare professionals and advocating for immunization awareness further supports vaccination efforts. Additionally, partnerships with pharmaceutical companies for research and production strengthen their influence in the vaccine market.

Country Analysis:

• Saudi Arabia
• Turkey
• Israel
• United Arab Emirates
• Egypt
• Iran
• Iraq
• Qatar
• Algeria
• Kuwait
• Morocco
• Oman
• Others
   

Saudi Arabia's vaccine market is expected to witness growth owing to the robust government healthcare initiatives, including the National Immunization Program, and the country's commitment towards eradication. Advanced healthcare infrastructure coupled with strong investments in COVID-19 vaccination campaigns have pushed Saudi Arabia ahead in vaccination coverage. Public awareness about vaccines and what it does to the person receiving the vaccine also boosts its demand with vaccination mandates for pilgrims during Hajj. In addition, partnerships formed with various pharmaceutical giants and the establishment of local manufacturing facilities enable efficient distribution and thus market growth.

In Turkey, the vaccine market benefits from its strategic location, advanced healthcare infrastructure, and robust government immunization programs. The Ministry of Health actively supports vaccination campaigns for diseases like hepatitis, influenza, and polio. Turkey’s expanding pharmaceutical industry, including local production of vaccines, ensures affordability and accessibility. High public health awareness and collaborations with global organizations for disease prevention also contribute to the growing demand for vaccines in the country.

Israel’s vaccine market is driven by its advanced healthcare system, strong government policies, and widespread immunization coverage. The country excels in vaccine distribution efficiency, supported by digital health records and centralized healthcare management. Israel’s focus on innovative vaccine technologies, including mRNA vaccines, and partnerships with pharmaceutical companies ensure quick adoption of new immunizations. Public trust in vaccines and the emphasis on preventive healthcare further strengthen Israel’s vaccine market.

The UAE’s vaccine market thrives on government-led healthcare reforms, high public health spending, and strong international partnerships. The country has implemented widespread vaccination campaigns, particularly for COVID-19, supported by advanced cold chain logistics. Public awareness, travel vaccination requirements, and mandatory school immunizations boost vaccine uptake. The UAE also positions itself as a regional hub for vaccine distribution and innovation, driving sustained market growth.

Egypt’s vaccine market is fueled by its large population, government immunization programs, and collaborations with global health organizations like WHO and UNICEF. Vaccines for diseases like polio, hepatitis, and measles are priorities. Increasing public awareness, urbanization, and investments in healthcare infrastructure improve vaccine accessibility. Local vaccine manufacturing initiatives and partnerships with international pharmaceutical companies also strengthen Egypt’s vaccine supply chain.

The vaccine market in Iran is mainly driven by government-sponsored immunization programs and domestic production ability for vaccines. Polio, measles, and influenza vaccines are widely used in Iran, especially for children's immunization. In addition to reducing reliance on imports, local advances in pharmaceuticals further complement wide international collaborations to maintain vaccine quality. Further, the commitment to self-reliance and increased access to health care in rural areas propels the country.

The international help and government initiatives in restoring healthcare infrastructure strengthen the vaccine market of Iraq. Polio and measles immunization campaigns are essential in the country to reduce disease prevalence. Partnerships with organizations such as UNICEF have facilitated vaccine supply even in conflict-affected areas. Efforts to improve vaccination awareness and accessibility, particularly among displaced populations, contribute to the market’s growth.

Qatar’s vaccine market benefits from its advanced healthcare system, mandatory vaccination policies, and high public awareness. The government invests heavily in immunization programs, covering diseases like influenza, hepatitis, and COVID-19. Qatar’s international collaborations and focus on preventive healthcare ensure a steady supply of high-quality vaccines. The country’s strategic position as a healthcare hub in the Gulf also supports vaccine distribution.

Algeria’s vaccine market is driven by government immunization programs targeting diseases like polio, hepatitis, and measles. Public health initiatives focus on expanding vaccine coverage in rural areas, supported by international organizations like WHO. Growing healthcare awareness and investments in cold chain infrastructure improve vaccine distribution. Algeria’s partnerships with global pharmaceutical companies also enhance vaccine availability and affordability.

Kuwait’s vaccine market is fueled by its strong healthcare infrastructure and government-led immunization campaigns. High public health expenditure ensures widespread vaccine availability for diseases like influenza, COVID-19, and hepatitis. Mandatory school vaccination policies and collaborations with global health organizations strengthen immunization efforts. Public awareness campaigns further drive vaccine adoption in Kuwait.

Morocco’s vaccine market benefits from government-backed immunization programs and partnerships with global organizations to combat diseases like polio, measles, and hepatitis. Improving the availability of vaccines is achieved through expanding healthcare infrastructure, particularly in rural regions. Immunization rates are influenced by public awareness campaigns and investments in regional vaccine manufacturing. Morocco's emphasis on healthcare prevention fosters steady market expansion.

Oman’s vaccine market is driven by government healthcare initiatives, mandatory immunization policies, and a well-established healthcare system. Public health campaigns are commonly used to give vaccines against diseases like polio, hepatitis, and influenza. The quality and accessibility of vaccines are guaranteed by the government's cooperation with international organizations. The market is growing because of Oman's emphasis on preventative care and high level of public trust in immunization programs.

Competitive Landscape:

The MENA vaccine market is highly competitive, with key players including global pharmaceutical companies such as Pfizer, Moderna, AstraZeneca, and Johnson & Johnson, alongside regional manufacturers like GSK and Serum Institute of India. These companies dominate with their extensive vaccine portfolios, including COVID-19 vaccines, routine immunization, and other infectious disease vaccines. Government partnerships and collaborations with international health organizations like the WHO are crucial for market access. For instance, in March 2024, The Kingdom of Saudi Arabia (KSA) and India entered a new strategic collaboration, characterized by mutual respect, common objectives, and a strong dedication to regional and international security.

Latest News and Developments:

• In May 2024, the Department of Health – Abu Dhabi (DoH) partnered with GSK to establish a regional vaccine distribution hub in Abu Dhabi, enhancing healthcare services and disease prevention. This collaboration, formalized during the Abu Dhabi Global Healthcare Week, aims to improve vaccine access across the Gulf, Near East, and South Asia. The initiative emphasizes innovation and robust immunization programs, aligning with the UAE's proactive healthcare vision.
• In November 2024, The United Arab Emirates (UAE) authorities approved KYOTOBIKEN's third bovine vaccine product, and the company launched the first batch on the market this month.
• In October 2024, the "Human Papillomavirus" vaccine was introduced in Kuwait to prevent different types of cancer, thus it placed the country at the very forefront of implementing this measure toward community health safety.

MENA Vaccine Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the MENA vaccine market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the MENA vaccine market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the MENA vaccine industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.